Aurinia Pharmaceuticals (AUPH) Accumulated Expenses (2023 - 2026)

Aurinia Pharmaceuticals has reported Accumulated Expenses for 4 years, with the latest figure at $58.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 37.41% year-over-year to $58.2 million; the trailing twelve-month figure through Mar 2026 stood at $58.2 million (up 37.41% YoY), and the FY2025 full-year result was $66.6 million, up 2.54% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $58.2 million, down from $66.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $66.6 million in Q4 2025, with the low at $42.4 million in Q1 2025.
• Historically, Accumulated Expenses has averaged $54.5 million across 4 years, with a median of $50.1 million in 2023.
• Annual changes were most pronounced in 2025 — Accumulated Expenses advanced 2.54% — and 2026, when it soared 37.41%.
• Aurinia Pharmaceuticals' Accumulated Expenses stood at $50.1 million in 2023, then advanced by 29.78% to $65.0 million in 2024, then grew by 2.54% to $66.6 million in 2025, then declined by 12.65% to $58.2 million in 2026.
• The last three Accumulated Expenses figures came in at $58.2 million (Q1 2026), $66.6 million (Q4 2025), and $49.5 million (Q3 2025), per Business Quant data.